Cantor Fitzgerald Maintains Overweight on Solid Biosciences, Raises Price Target to $26

Benzinga Newsdesk www.benzinga.com Positive 90.0%

Neg 0% Neu 0% Pos 90%

Cantor Fitzgerald analyst Kristen Kluska maintains Solid Biosciences (NASDAQ:SLDB) with a Overweight and raises the price target from $16 to $26.